Regenxbio Inc (RGNX)
15.30
-0.42
(-2.67%)
USD |
NASDAQ |
May 10, 12:21
Regenxbio Cash from Financing (Quarterly): -11.96M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.96M |
| September 30, 2023 | -4.805M |
| June 30, 2023 | -9.162M |
| March 31, 2023 | -9.037M |
| December 31, 2022 | -8.92M |
| September 30, 2022 | -5.417M |
| June 30, 2022 | -7.669M |
| March 31, 2022 | -6.834M |
| December 31, 2021 | -7.616M |
| September 30, 2021 | -2.283M |
| June 30, 2021 | -6.137M |
| March 31, 2021 | 211.29M |
| December 31, 2020 | 194.17M |
| September 30, 2020 | 1.46M |
| June 30, 2020 | 1.825M |
| March 31, 2020 | 2.761M |
| December 31, 2019 | 1.549M |
| September 30, 2019 | 1.333M |
| Date | Value |
|---|---|
| June 30, 2019 | 1.367M |
| March 31, 2019 | 4.127M |
| December 31, 2018 | 5.288M |
| September 30, 2018 | 191.81M |
| June 30, 2018 | 3.175M |
| March 31, 2018 | 4.166M |
| December 31, 2017 | 1.741M |
| September 30, 2017 | 0.606M |
| June 30, 2017 | 10.73M |
| March 31, 2017 | 71.52M |
| December 31, 2016 | -0.055M |
| September 30, 2016 | 0.044M |
| June 30, 2016 | 0.109M |
| March 31, 2016 | 0.021M |
| December 31, 2015 | -2.424M |
| September 30, 2015 | 147.65M |
| June 30, 2015 | 68.06M |
| March 31, 2015 | 26.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.96M
Minimum
Dec 2023
211.29M
Maximum
Mar 2021
17.68M
Average
-4.805M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 22.14M |
| Amgen Inc | -1.708B |
| Gilead Sciences Inc | -1.361B |
| AbbVie Inc | 10.82B |
| Bristol-Myers Squibb Co | 14.64B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -40.76M |
| Cash from Investing (Quarterly) | 33.97M |
| Free Cash Flow | -228.37M |
| Free Cash Flow Per Share (Quarterly) | -0.9519 |
| Free Cash Flow to Equity (Quarterly) | -41.89M |
| Free Cash Flow to Firm (Quarterly) | -40.39M |
| Free Cash Flow Yield | -34.13% |